Wedbush Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $40
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst David Nierengarten has initiated coverage on Apogee Therapeutics (NASDAQ:APGE) with an Outperform rating and a price target of $40.
August 08, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apogee Therapeutics has been given an Outperform rating by Wedbush with a price target of $40.
The Outperform rating from Wedbush indicates a positive outlook for Apogee Therapeutics. The price target of $40 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100